Viral vectors are sophisticated tools widely used by molecular biologists to deliver genetic material.
It is performed inside a living organism or in cell culture. Viral vectors are derived from parental wild-type viruses whose viral genes have been replaced with heterologous genes intended for cell manipulation. It is used as an in-vitro tool to study biomolecules and gene functions and gene therapy, treat genetic disorders, fight cancers, drive tissue regeneration, monitor cell function, and develop vaccines.
The global Viral Vector Manufacturing market size was valued at USD 424.01 million in 2019 and projected to reach USD 1733.41 million by 2027, growing at a CAGR of 19% during the forecast period, 2020-2027. The major factors are the growing prevalence of target diseases such as diphtheria, measles, poliomyelitis, pertussis, tuberculosis, and tetanus and rising cancer and other infectious diseases. Additionally, the increasing utilization of viral vectors for the development of gene therapy, rising clinical trials, and increasing R&D investments will spur the global viral vector industry in the future periods. Furthermore, the growing public-private funding for viral vectors activities and the development of DNA vaccines are expected to witness remarkable growth of the viral vectors market. The increasing investments in biopharmaceutical production and efficient ability to express the therapeutic genes, and non-pathogenic nature are the factors that are expected to propel the demand for viral vectors over the coming years.
Read Full Report: Viral Vectors Manufacturing Market